<DOC>
	<DOCNO>NCT02158624</DOCNO>
	<brief_summary>To establish correlation visual acuity improvement QOL measurement ranibizumab treatment AMD patient .</brief_summary>
	<brief_title>Ranibizumab Treatment Age-Related Macular Degeneretion</brief_title>
	<detailed_description />
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Active primary recurrent subfoveal choroidal neovascularization lesion due AMD Subjects either gender age 50 year old Visual acuity well 0.05 decimal ( 20/400 Snellen ) Signed informed consent form Prior treatment neovascular AMD study eye , example , PDT antiVEGF therapy Patients whose lesion site evaluate FA examination 12DA subject eye Patients treatment triamcinolone intravitreal injection within 6 month subject eye Patients history intraocular surgical operation ( include cataract ) within 3 month subject eye Patients serious allergic history fluorescein , indocyanine green , iodophors The pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>